Published in:
Open Access 01-12-2018 | Case report
Favorable effect of bortezomib in dense deposit disease associated with monoclonal gammopathy: a case report
Published in: BMC Nephrology | Issue 1/2018
Login to get accessAbstract
Background
Complement component 3 (C3) glomerulopathy, which includes dense deposit disease (DDD) and C3 glomerulonephritis, is caused by dysregulation of the alternative complement pathway. In most cases, C3 glomerulopathy manifests pathologically with membranoproliferative glomerulonephritis-like features. An association between C3 glomerulopathy and monoclonal gammopathy was recently reported in several cases, raising the possibility that C3 glomerulopathy is the underlying pathological process in monoclonal gammopathy of renal significance.
Case presentation
We herein report a case of monoclonal gammopathy-induced DDD that improved histologically and clinically with chemotherapy including bortezomib. Our case is the first in which treatment response can be linked to the histological response. Potential pathological insights are also discussed.
Conclusions
Rapid and efficient chemotherapy has the potential to limit renal damage in monoclonal gammopathy-associated DDD.